CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...

NeoADAURA: Can We Afford to Overlook Objective Response Rates? The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated ...

Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...

In a 2025 JAMA Network Open invited commentary, Melina E. Marmarelis, MD, MSCE, and Lauren Reed-Guy, MD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, ...

Use of neoadjuvant or perioperative immunotherapy in combination with chemotherapy has proven effective for some patients with non-small cell lung cancer (NSCLC), but its role in patients with EGFR- ...

FREMONT, Calif., September 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical ...

Dr Jonathan Goldman of the University of California, Los Angeles, highlights key abstracts in early-stage NSCLC from ASCO 2025. Dr Goldman begins with updated results from CheckMate 816, comparing ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. Some cancer cells have changes in particular genes and proteins. For example, a change in the ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

This trial is no longer recruiting patients. We hope to add results when they are available. This trial is looking at adding osimertinib to chemotherapy before surgery for non small cell lung cancer ...